LL-37 Peptide Shows Potent Antimicrobial Activity Against Root Canal Bacteria
Background
Periapical infections, often leading to periapical periodontitis (inflammation and infection around the tooth root), are a significant challenge in dentistry. These infections are typically polymicrobial, involving a complex array of bacteria that can be difficult to eradicate with conventional treatments, leading to persistent symptoms and treatment failures. Current antimicrobial strategies, while effective, face issues like bacterial resistance and limited penetration into the complex root canal system. This study addresses the critical need for novel, effective antimicrobial agents to combat these resistant periapical pathogens.
Results
The study revealed that LL-37 peptide exhibited significant antimicrobial activity against all tested periapical pathogens in a concentration-dependent manner. The MIC50 values for most strains ranged between 2 µM and 8 µM, indicating potent inhibitory effects. Specifically, LL-37 at 10 µM achieved a 90% reduction in viable Porphyromonas gingivalis cells within 24 hours (p<0.001) compared to untreated controls. Furthermore, at 20 µM, the peptide demonstrated bactericidal activity, reducing Enterococcus faecalis counts by 99% (p<0.001). > The most impactful finding was LL-37's ability to significantly inhibit and disrupt mature bacterial biofilms, reducing biofilm biomass by 65% at 10 µM (p<0.01) across multiple species, a 2.5-fold greater reduction than standard chlorhexidine at comparable concentrations.
Why It Matters
This research highlights the significant potential of LL-37 peptide as a novel therapeutic agent for treating complex periapical infections, especially given its broad-spectrum activity and biofilm-disrupting capabilities. The ability of LL-37 to target both planktonic bacteria and their protective biofilms is a critical advantage over existing treatments, which often struggle with biofilm penetration. These findings strongly suggest that LL-37 could be developed into an innovative adjunctive therapy or a standalone antimicrobial for root canal disinfection, potentially improving treatment outcomes and reducing recurrence rates. Future steps should include in vivo studies to assess its efficacy and safety in animal models, followed by formulation development for clinical application.